# US 2026/0097077 A1 · Methods and compositions for cancer therapy using modified gamma delta T cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097077 A1
- Document ID: US20260097077A1
- Status: Published application
- Kind: A1
- Application number: 19/318,631
- Filed: 2025-09-04
- Published: 2026-04-09
- Earliest claimed: 2024-10-07
- Assignees: Research & Business Foundation Sungkyunkwan University; National Cancer Center
- Applicants: Research & Business Foundation SUNGKYUNKWAN UNIVERSITY; National Cancer Center
- Inventors: Minkyung SONG; Hocheol SHIN; Ji Yun PARK
- Web page: https://patentgrep.com/patent/US20260097077A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61P 35/00: Antineoplastic agents
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a method for treating cancer, comprising administering a composition comprising γδ T cells treated with an inhibitor of XBP1 gene expression or an inhibitor of XBP1 protein expression or activity. The γδ T cells, in which the XBP1 gene is deficient or the XBP1 protein activity is inhibited, exhibit enhanced antitumor activity in a tumor microenvironment characterized by endoplasmic reticulum (ER) stress, as compared to unmodified γδ T cells. Accordingly, the modified γδ T cells are effective for use in cancer treatment.

## Claims

### Claim 1

A method for treating cancer in a subject in need thereof, the method comprising:
administering a therapeutically effective amount of a composition comprising γδ T cells modified by an inhibitor of X-box binding protein 1 (XBP1) gene expression or an inhibitor of XBP1 protein expression or activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor of XBP1 gene expression is selected from the group consisting of microRNA (miRNA), small interfering RNA (siRNA), small hairpin RNA (shRNA), single guide RNA (sgRNA), guide RNA (gRNA), antisense oligonucleotides, and ribozymes, which specifically bind to the XBP1 gene.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitor of XBP1 gene expression is a sgRNA comprising the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitor of XBP1 protein expression or activity is selected from the group consisting of an antibody, an aptamer, a peptide nucleic acid (PNA), a peptide, a peptidomimetic, a targeted protein degrader (TPD), and a small molecule compound, which inhibits XBP1 protein expression or activity.

### Claim 5 (depends on 1)

The method of claim 1, wherein the γδ T cells are deficient in the XBP1 gene.

### Claim 6 (depends on 1)

The method of claim 1, wherein the γδ T cells reduce the XBP1 protein expression or activity.

### Claim 7 (depends on 1)

The method of claim 1, wherein the γδ T cells exhibit enhanced anticancer activity relative to unmodified γδ T cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of ovarian cancer, cholangiocarcinoma, bile duct cancer, pancreatic cancer, breast cancer, kidney cancer, gastric cancer, lung cancer, liver cancer, colorectal cancer, skin cancer, bladder cancer, testicular cancer, uterine cancer, cervical cancer, thyroid cancer, brain tumor, head and neck cancer, prostate cancer, non-small cell lung cancer, colon cancer, squamous cell carcinoma, melanoma, myeloma, lymphoma, and leukemia.

### Claim 9 (depends on 1)

The method of claim 1, wherein the γδ T cells are isolated from peripheral blood mononuclear cells (PBMCs).

### Claim 10 (depends on 9)

The method of claim 9, wherein the peripheral blood mononuclear cells (PBMCs) are obtained from a subject in need of cancer treatment.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method is for personalized treatment.

### Claim 12

A method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of:
(a) a first agent comprising an inhibitor of XBP1 expression; and
(b) a second agent comprising γδ T cells,
wherein the combined administration of (a) and (b) enhances antitumor activity.

### Claim 13 (depends on 12)

The method of claim 12, wherein the first agent and the second agent are formulated separately and are administered simultaneously or sequentially.

### Claim 14

A method for manufacturing cell therapy composition for treating cancer, the method comprising:
(a) isolating γδ T cells from peripheral blood mononuclear cells (PBMCs); and
(b) generating XBP1-deficient γδ T cells by inhibiting or deleting the XBP1 gene in the γδ T cells isolated in step (a).

### Claim 15 (depends on 14)

The method of claim 14, wherein the XBP1-deficient γδ T cells are generated using a CRISPR/Cas9 system.

### Claim 16 (depends on 15)

The method of claim 15, wherein the CRISPR/Cas9 system is delivered into the cells via lentivirus.

### Claim 17 (depends on 14)

The method of claim 14, wherein the XBP1 gene is inhibited or deleted by using a nucleic acid selected from the group consisting of siRNA, shRNA, sgRNA, gRNA, and antisense oligonucleotides.

### Claim 18 (depends on 14)

The method of claim 14, wherein the XBP1 gene is inhibited or deleted by using a sgRNA comprising the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 19 (depends on 14)

The method of claim 14, wherein the peripheral blood mononuclear cells (PBMCs) are isolated from a subject in need of cancer treatment.

### Claim 20 (depends on 14)

The method of claim 14, further comprising expanding the XBP1-deficient γδ T cells ex vivo before formulating them into a pharmaceutical composition.
